A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in Patients With Duodenal Ulcer.

Trial Profile

A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in Patients With Duodenal Ulcer.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Nov 2016

At a glance

  • Drugs Vonoprazan (Primary) ; Lansoprazole
  • Indications Duodenal ulcer
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 27 Nov 2016 Primary endpoint (Endoscopic Healing Rate of Duodenal Ulcer Over 6 Weeks) has not been met according to the results published in the Alimentary Pharmacology and Therapeutics.
    • 27 Nov 2016 Results published in the Alimentary Pharmacology and Therapeutics.
    • 12 Jan 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top